Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ED90 of liposomal bupivacaine vs bupivacaine hydrochloride for stellate ganglion block
ChiCTR2600116174Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Dali University
- Start
- Jan 2026
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised trial comparing Liposomal Bupivacaine Group with Bupivacaine Hydrochloride Group (2 arms). Primary endpoint: ED90 of the drug. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
liposomal bupivacainebupivacaine
Beyond the preview
Go deeper on ChiCTR2600116174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600116174.